Pixium Vision (PIX) - Focus shifts to Prima as human trials proceed

04:27 EST 8 Mar 2018 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - Pixium Vision: Pixium Vision is developing Prima, a potentially breakthrough wireless sub-retinal implant that generates electrical impulses at the retinal bipolar cell level to restore a form of central visual perception in patients with advanced retinal disease. While competing retinal implants generally target rare conditions involving near-total blindness, Prima seeks to address initially a larger unmet market indication, dry age-related macular degeneration (Dry-ARMD). Prima started human feasibility studies in late 2017 and could start EU pivotal trials in H119. Using a risk-adjusted NPV model, we obtain a pipeline rNPV of €77.4m, down from €82.6m previously.
ISIN: FR0011950641

Original Article: Pixium Vision (PIX) - Focus shifts to Prima as human trials proceed


More From BioPortfolio on "Pixium Vision (PIX) - Focus shifts to Prima as human trials proceed"

Quick Search


Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Bipolar Disorders
Bipolar disorder, also known as manic-depressive illness, is a brain disorder that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks. Over half of Bipolar cases develops before the age of 25. Bipolar ...